Researchers with the Fatty Acid Research Institute, in collaboration with Cedars-Sinai Medical Center in Los Angeles, CA, recently posted the results of a pilot study which found a potential link between low Omega-3 Index levels and mortality from COVID-19 infection.
Photo © iStockphoto.com/nicolas_
Researchers with the Fatty Acid Research Institute, in collaboration with Cedars-Sinai Medical Center in Los Angeles, CA, recently posted the results of a pilot study1 which found a potential link between low Omega-3 Index levels and mortality from COVID-19 infection. The study included 100 patients admitted into the hospital with COVID-19, whose blood samples were analyzed for omega-3 levels, and grouped into four quartiles based on Omega-3 Index.
There was one death in the top quartile (Omega-3 Index >5.7%), and 13 deaths in in the lower three quartiles (Omega-3 Index <5.7%). In age-and-sex adjusted regression analyses, patients in the highest quartile were 75% less likely to die compared those in the lower three quartiles, meaning the relative risk of death was four times higher in those with a lower Omega-3 Index compared to those with higher levels.
“While not meeting standard statistical significance thresholds, this pilot study – along with multiple lines of evidence regarding the anti-inflammatory effects of EPA and DHA – strongly suggests that these nutritionally available marine fatty acids may help reduce risk for adverse outcomes in COVID-19 patients. Larger studies are clearly needed to confirm these preliminary findings,” said Arash Asher, MD, the lead author on this study, in a press release.
An omega-3 expert not involved with the trial, James H. O’Keefe, Jr., MD, director of Preventive Cardiology, Saint Luke’s Mid America Heart Institute (Kansas City, MO) observed in a press release, “An excessive inflammatory response, referred to as a ‘cytokine storm,’ is a fundamental mediator of severe COVID-19 illness. Omega-3 fatty acids (DHA and EPA) have potent anti-inflammatory activities, and this pilot study provides suggestive evidence that these fatty acids may dampen COVID-19’s cytokine storm.”
The research team is currently seeking funding to expand upon the preliminary observations found in the pilot study.
Reference
PLT Health Solution's Bosewellia serrata extract granted updated license by Health Canada
August 27th 2024The Natural and Non-Prescription Health Products Directorate (NNPHD) of Health Canada has granted PLT Health Solutions an updated license to market its AprèsFlex 5-Day Joint Support Ingredient in Canada.
GC Rieber VivoMega uses AI platform from Intelecy to boost efficiency, quality, and sustainability
August 26th 2024According to the company’s announcement, the AI platform is able to identify real-time deviations or anomalies in GC Rieber VivoMega’s processing facilities and report them via a cloud-based, comprehensive, centralized system.